Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 11/20 | 1.00 |
| ▸ | PARP1 | P09874 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19497773 | 0.85 | GSTO1 (1.00) | GSTO1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19974143 | 0.84 | PARP1 (0.76) | GSTO1PARP1MAPTADORA3LMNA | |
| SCHEMBL19974141 | 0.84 | PARP1 (0.76) | GSTO1PARP1MAPTADORA3LMNA | |
| SCHEMBL6484541 | 0.83 | GSTO1 (0.71) | GSTO1PARP1MAPTADORA3LMNA | |
| SCHEMBL10813540 | 0.83 | MAPT (0.88) | GSTO1PARP1MAPTADORA3LMNA | |
| SCHEMBL10921715 | 0.83 | MAPT (0.72) | GSTO1PARP1MAPTADORA3LMNA | |
| SCHEMBL3823589 | 0.83 | MAPT (0.72) | GSTO1PARP1MAPTADORA3LMNA | |
| SCHEMBL2020280 | 0.80 | ABL1 (0.73) | GSTO1PARP1MAPTADORA3LMNA | |
| SCHEMBL1325353 | 0.80 | MAPT (0.68) | GSTO1PARP1MAPTADORA3LMNA | |
| SCHEMBL11136424 | 0.80 | MAPT (0.68) | GSTO1PARP1MAPTADORA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| WO-2019201865-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201867-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | GSTO1 3158/4885PARP1 62/4885MAPT 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.